ES3011058T3 - Bicyclic bet bromodomain inhibitors and uses thereof - Google Patents
Bicyclic bet bromodomain inhibitors and uses thereof Download PDFInfo
- Publication number
- ES3011058T3 ES3011058T3 ES22162126T ES22162126T ES3011058T3 ES 3011058 T3 ES3011058 T3 ES 3011058T3 ES 22162126 T ES22162126 T ES 22162126T ES 22162126 T ES22162126 T ES 22162126T ES 3011058 T3 ES3011058 T3 ES 3011058T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- independently selected
- group
- dimethylisoxazol
- quinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259894P | 2015-11-25 | 2015-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3011058T3 true ES3011058T3 (en) | 2025-04-07 |
Family
ID=57543210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22162126T Active ES3011058T3 (en) | 2015-11-25 | 2016-11-23 | Bicyclic bet bromodomain inhibitors and uses thereof |
| ES16810193T Active ES2918589T3 (es) | 2015-11-25 | 2016-11-23 | Inhibidores de bromodomios BET bicíclicos y usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16810193T Active ES2918589T3 (es) | 2015-11-25 | 2016-11-23 | Inhibidores de bromodomios BET bicíclicos y usos de los mismos |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10508106B2 (https=) |
| EP (2) | EP3380469B1 (https=) |
| JP (2) | JP6882289B2 (https=) |
| CN (2) | CN109641886B (https=) |
| AU (3) | AU2016361441B2 (https=) |
| CA (1) | CA3006300C (https=) |
| ES (2) | ES3011058T3 (https=) |
| WO (1) | WO2017091661A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108314680A (zh) * | 2017-01-16 | 2018-07-24 | 凯惠科技发展(上海)有限公司 | 一种含芳环化合物、其制备方法、药物组合物及应用 |
| CN109111426B (zh) * | 2017-06-23 | 2021-12-14 | 中国科学院上海药物研究所 | 一类稠合双环杂芳基或芳基化合物，及其用途 |
| WO2019201296A1 (zh) * | 2018-04-18 | 2019-10-24 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的吡唑类化合物 |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| EP4424379A3 (en) * | 2019-04-24 | 2024-10-30 | Convergene Llc | Small molecule bromodomain inhibitors and uses thereof |
| BR112021022099A2 (pt) * | 2019-05-31 | 2021-12-28 | Chiesi Farm Spa | Derivados de amino quinazolina como inibidores de p2x3 |
| CN114222741B (zh) * | 2019-05-31 | 2025-12-30 | 奇斯药制品公司 | 作为p2x3抑制剂的吡啶并嘧啶类衍生物 |
| EP4234548A4 (en) * | 2020-10-20 | 2024-10-23 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, ITS PREPARATION METHOD AND ITS APPLICATION |
| WO2022161461A1 (zh) * | 2021-01-29 | 2022-08-04 | 江苏先声药业有限公司 | Sos1抑制剂及其制备方法和应用 |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| EP4291195A4 (en) * | 2021-02-11 | 2025-07-09 | Medical College Wisconsin Inc | SMALL MOLECULE INHIBITORS OF PBRM1-BD2 |
| CN119630431A (zh) * | 2022-08-26 | 2025-03-14 | 卫材R&D管理有限公司 | 抗体药物缀合物 |
| WO2024235225A1 (zh) * | 2023-05-15 | 2024-11-21 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并环类抑制剂及其制备方法和应用 |
| WO2025209570A1 (zh) * | 2024-04-03 | 2025-10-09 | 北京大学 | Bet抑制剂及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| GB8908229D0 (en) * | 1989-04-12 | 1989-05-24 | Smithkline Beckman Intercredit | Compounds |
| FI940469L (fi) | 1991-08-02 | 1994-02-01 | Pfizer | Kinoliinijohdannaisia immunostimulantteina |
| WO1999011658A1 (en) * | 1997-08-29 | 1999-03-11 | Proteus Molecular Design Ltd. | Meta-benzamidine derivatives as serin protease inhibitors |
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| SE0102858D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP4934432B2 (ja) * | 2004-02-19 | 2012-05-16 | レクサン ファーマシューティカルズ インコーポレイテッド | キナゾリン誘導体およびキナゾリン誘導体の治療への使用 |
| KR100910333B1 (ko) * | 2005-02-23 | 2009-07-31 | 시오노기세이야쿠가부시키가이샤 | 타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체 |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| WO2006121767A2 (en) | 2005-05-06 | 2006-11-16 | Apath, Llc | 4-aminoquinoline compounds for treating virus-related conditions |
| WO2008054599A2 (en) | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
| US20080200458A1 (en) * | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| GB0705915D0 (en) * | 2007-03-28 | 2007-05-09 | Helperby Therapeutics Ltd | New use |
| EP2152672A1 (en) * | 2007-05-24 | 2010-02-17 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| JP5301456B2 (ja) * | 2007-11-12 | 2013-09-25 | Ｍｓｄ株式会社 | ヘテロアリールオキシキナゾリン誘導体 |
| EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| US20110135655A1 (en) * | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| EP2566477B1 (en) * | 2010-05-07 | 2015-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| US8933096B2 (en) * | 2010-06-09 | 2015-01-13 | Rugers, The State University of New Jersey | Antimicrobial agents |
| AU2011289230B2 (en) | 2010-08-13 | 2014-09-04 | Janssen Pharmaceutica Nv | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
| WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| WO2012125913A1 (en) * | 2011-03-17 | 2012-09-20 | The Trustees Of The University Of Pennsylvania | Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| GB201106799D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| KR20140048216A (ko) | 2011-06-29 | 2014-04-23 | 오츠카 세이야쿠 가부시키가이샤 | 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법 |
| EP2788332A1 (en) * | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US20130225611A1 (en) * | 2011-12-09 | 2013-08-29 | The Regents Of The University Of California | Compositions and Methods for Reducing Cancer Cell Proliferation and Modulating Importin-Beta Function |
| US20130281397A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9201821B2 (en) * | 2012-09-27 | 2015-12-01 | Apple Inc. | Interrupt timestamping |
| KR20150072412A (ko) * | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 억제제 |
| US9977024B2 (en) * | 2012-12-09 | 2018-05-22 | The Scripps Research Institute | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines |
| WO2014100501A1 (en) * | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| JP6464139B2 (ja) * | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| EP3010918B1 (en) * | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| WO2015112739A1 (en) * | 2014-01-22 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for treating parp1-deficient cancers |
| CN106536507B (zh) * | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| US11034757B2 (en) * | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| JP6599908B2 (ja) * | 2014-06-25 | 2019-10-30 | サンフォード−バーンハム メディカル リサーチ インスティテュート | ニューロテンシン受容体１の小分子アゴニスト |
| US10106507B2 (en) * | 2014-08-03 | 2018-10-23 | H. Lee Moffitt Cancer Center and Research Insitute, Inc. | Potent dual BRD4-kinase inhibitors as cancer therapeutics |
| WO2016120808A1 (en) | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
| EP3072891A1 (en) * | 2015-03-24 | 2016-09-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | New Toll-Like Receptor 9 Antagonists |
| JP2018525345A (ja) * | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
-
2016
- 2016-11-23 CA CA3006300A patent/CA3006300C/en active Active
- 2016-11-23 CN CN201680079771.1A patent/CN109641886B/zh active Active
- 2016-11-23 ES ES22162126T patent/ES3011058T3/es active Active
- 2016-11-23 WO PCT/US2016/063485 patent/WO2017091661A1/en not_active Ceased
- 2016-11-23 EP EP16810193.9A patent/EP3380469B1/en active Active
- 2016-11-23 CN CN202211334125.9A patent/CN115806550B/zh active Active
- 2016-11-23 US US15/779,353 patent/US10508106B2/en active Active
- 2016-11-23 EP EP22162126.1A patent/EP4050005B1/en active Active
- 2016-11-23 AU AU2016361441A patent/AU2016361441B2/en active Active
- 2016-11-23 JP JP2018527799A patent/JP6882289B2/ja active Active
- 2016-11-23 ES ES16810193T patent/ES2918589T3/es active Active
-
2019
- 2019-11-15 US US16/685,128 patent/US11028079B2/en active Active
-
2021
- 2021-05-06 JP JP2021078741A patent/JP7112567B2/ja active Active
- 2021-07-28 AU AU2021209257A patent/AU2021209257B2/en active Active
-
2024
- 2024-03-22 AU AU2024201890A patent/AU2024201890A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017091661A1 (en) | 2017-06-01 |
| CN109641886B (zh) | 2022-11-18 |
| US10508106B2 (en) | 2019-12-17 |
| ES2918589T3 (es) | 2022-07-19 |
| EP4050005B1 (en) | 2024-12-25 |
| CA3006300C (en) | 2024-02-27 |
| EP4050005A1 (en) | 2022-08-31 |
| EP3380469A1 (en) | 2018-10-03 |
| CN109641886A (zh) | 2019-04-16 |
| EP3380469B1 (en) | 2022-03-16 |
| CN115806550A (zh) | 2023-03-17 |
| US20200223836A1 (en) | 2020-07-16 |
| AU2016361441B2 (en) | 2021-08-12 |
| JP2021119188A (ja) | 2021-08-12 |
| JP7112567B2 (ja) | 2022-08-03 |
| AU2016361441A1 (en) | 2018-06-21 |
| US11028079B2 (en) | 2021-06-08 |
| US20180305344A1 (en) | 2018-10-25 |
| CN115806550B (zh) | 2025-11-28 |
| JP2019501140A (ja) | 2019-01-17 |
| AU2021209257A1 (en) | 2021-08-19 |
| CA3006300A1 (en) | 2017-06-01 |
| AU2021209257B2 (en) | 2023-12-21 |
| JP6882289B2 (ja) | 2021-06-02 |
| AU2024201890A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3011058T3 (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| ES2951212T3 (es) | Fenilacetamidas como inhibidores de ROCK | |
| ES2708211T3 (es) | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas | |
| ES2634628T3 (es) | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK | |
| ES2838573T3 (es) | Derivados de benzamida ligados como inhibidores potentes de ROCK | |
| ES2730112T3 (es) | Lactamas como inhibidores de ROCK | |
| ES2944304T3 (es) | Pirazol azinas de ácido ciclohexílico como antagonistas de LPA | |
| ES2997111T3 (en) | Pyridazinyl amino derivatives as alk5 inhibitors | |
| KR20170118688A (ko) | 브로모도메인 및 추가 말단 단백질의 저해를 위한 방법 및 조성물 | |
| CN111918863B (zh) | 杂环化合物 | |
| ES2686828T3 (es) | Derivados de poliéteres macrocíclicos de N-aril-2-amino-4-aril-pirimidinas como inhibidores de la FLT3 y JAK | |
| HK40078733B (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK40078733A (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| JP2024510762A (ja) | 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用 | |
| HK1261992B (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK1261992A1 (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| EP4665733A1 (en) | Amino-substituted pyrrolotriazine derivatives as inhibitors of sgk1 | |
| BR112017025356B1 (pt) | Composto, composição farmacêutica, e, uso para a fabricação de um medicamento |